The biotechnology sector is undergoing significant transformation driven by artificial intelligence (AI) and the challenges posed by the "patent cliff." This latter issue, representing a potential loss of $400 billion, compels companies to innovate rapidly to compensate for the loss of patents. AI, as an innovation catalyst, plays a crucial role in drug discovery and the optimization of research and development (R&D) processes. Recent strategic partnerships, such as the one between Eli Lilly and BigHat Biosciences, exemplify the growing integration of AI into the industry, promising to accelerate pharmaceutical development.